Cochrane · systematic review · CD001415
Gabapentin add‐on treatment for drug‐resistant focal epilepsy
Panebianco, M, Al-Bachari, S, Hutton, JL, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
8
current version
GRADE rated
8
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 25%Moderate 6 · 75%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyGabapentin versus placebo for people with drug‐resistant focal epilepsy
Population: people with drug‐resistant focal epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Reduction in seizure frequency of ≥ 50%: primary analysisNumber of seizures reported in seizure diary Gabapentin vs placebo | RR 1.89 [1.4, 2.55] | 6 studies · 1206 participants | Moderate Downgraded: risk of bias |
Treatment withdrawalNumber of participants withdrawn for any reason Gabapentin vs placebo | RR 1.05 [0.74, 1.49] | 6 studies · 1206 participants | Moderate Downgraded: risk of bias |
Adverse effects: ataxiaNumber of participants experiencing ataxia Gabapentin vs placebo | RR 2.01 | 3 studies · 787 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects: dizzinessNumber of participants experiencing dizziness Gabapentin vs placebo | RR 2.43 | 6 studies · 1206 participants | Moderate Downgraded: risk of bias |
Adverse effects: fatigueNumber of participants experiencing fatigue Gabapentin vs placebo | RR 1.95 | 5 studies · 1161 participants | Low Downgraded: risk of bias, imprecision, publication bias |
Adverse effects: nauseaNumber of participants experiencing nausea Gabapentin vs placebo | RR 0.95 | 4 studies · 1034 participants | Moderate Downgraded: risk of bias |
Adverse effects: somnolenceNumber of participants experiencing somnolence Gabapentin vs placebo | RR 1.93 | 6 studies · 1206 participants | Moderate Downgraded: risk of bias |
Adverse effects: headacheNumber of participants experiencing headache Gabapentin vs placebo | RR 0.79 | 6 studies · 1206 participants | Moderate Downgraded: risk of bias |
Gabapentin versus placebo for people with drug‐resistant focal epilepsy
Population: people with drug‐resistant focal epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Reduction in seizure frequency of ≥ 50%: primary analysis Number of seizures reported in seizure diary Gabapentin vs placebo | RR 1.89 [1.4, 2.55] | 6 studies · 1206 participants | Moderate Downgraded: risk of bias |
Treatment withdrawal Number of participants withdrawn for any reason Gabapentin vs placebo | RR 1.05 [0.74, 1.49] | 6 studies · 1206 participants | Moderate Downgraded: risk of bias |
Adverse effects: ataxia Number of participants experiencing ataxia Gabapentin vs placebo | RR 2.01 | 3 studies · 787 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects: dizziness Number of participants experiencing dizziness Gabapentin vs placebo | RR 2.43 | 6 studies · 1206 participants | Moderate Downgraded: risk of bias |
Adverse effects: fatigue Number of participants experiencing fatigue Gabapentin vs placebo | RR 1.95 | 5 studies · 1161 participants | Low Downgraded: risk of bias, imprecision, publication bias |
Adverse effects: nausea Number of participants experiencing nausea Gabapentin vs placebo | RR 0.95 | 4 studies · 1034 participants | Moderate Downgraded: risk of bias |
Adverse effects: somnolence Number of participants experiencing somnolence Gabapentin vs placebo | RR 1.93 | 6 studies · 1206 participants | Moderate Downgraded: risk of bias |
Adverse effects: headache Number of participants experiencing headache Gabapentin vs placebo | RR 0.79 | 6 studies · 1206 participants | Moderate Downgraded: risk of bias |
Gabapentin versus placebo for drug‐resistant partial epilepsy patients
Population: drug‐resistant partial epilepsy patients
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
50% reduction in seizure frequency ‐ primary analysis Number of seizures reported in seizure diary Gabapentin vs placebo | RR 1.89 [1.4, 2.55] | 6 studies · 1206 participants | Moderate |
Drug withdrawal Number of patients withdrawn for any reason Gabapentin vs placebo | RR 1.05 [0.74, 1.49] | 6 studies · 1206 participants | Moderate |
Adverse effects ‐ ataxia Number of patients experiencing ataxia Gabapentin vs placebo | no estimate extracted | 3 studies · 787 participants | Low Downgraded: imprecision |
Adverse effects ‐ dizziness Number of people experiencing dizziness Gabapentin vs placebo | no estimate extracted | 6 studies · 1206 participants | Moderate |
Adverse effects ‐ fatigue Number of patients experiencing fatigue Gabapentin vs placebo | no estimate extracted | 5 studies · 1161 participants | Low Downgraded: imprecision, publication bias |
Adverse effects ‐ nausea Number of patients experiencing nausea Gabapentin vs placebo | no estimate extracted | 4 studies · 1034 participants | Moderate |
Adverse effects ‐ somnolence Number of patients experiencing somnolence Gabapentin vs placebo | no estimate extracted | 6 studies · 1206 participants | Moderate |